Non-alcoholic fatty liver disease: modern methods of diagnostics and treatment strategies

2020 ◽  
Vol 0 (3) ◽  
pp. 51-61
Author(s):  
I. E. Kushnir
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Treatment Strategies ◽  
Alcoholic Fatty Liver ◽  
Modern Methods ◽  
Alcoholic Fatty Liver Disease

scholarly journals Murine models provide insight to the development of non-alcoholic fatty liver disease

2015 ◽  
Vol 28 (2) ◽  
pp. 133-142 ◽  
Author(s):  
D. T. Reid ◽  
B. Eksteen
Keyword(s):  
Animal Model ◽  
Liver Disease ◽  
Animal Models ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Treatment Strategies ◽  
Alcoholic Fatty Liver ◽  
Advantages And Disadvantages ◽  
The Metabolic Syndrome ◽  
Alcoholic Fatty Liver Disease

AbstractAssociated with the obesity epidemic, non-alcoholic fatty liver disease (NAFLD) has become the leading liver disease in North America. Approximately 30 % of patients with NAFLD may develop non-alcoholic steatohepatitis (NASH) that can lead to cirrhosis and hepatocellular carcinoma (HCC). Frequently animal models are used to help identify underlying factors contributing to NAFLD including insulin resistance, dysregulated lipid metabolism and mitochondrial stress. However, studying the inflammatory, progressive nature of NASH in the context of obesity has proven to be a challenge in mice. Although the development of effective treatment strategies for NAFLD and NASH is gaining momentum, the field is hindered by a lack of a concise animal model that reflects the development of liver disease during obesity and the metabolic syndrome. Therefore, selecting an animal model to study NAFLD or NASH must be done carefully to ensure the optimal application. The most widely used animal models have been reviewed highlighting their advantages and disadvantages to studying NAFLD and NASH specifically in the context of obesity.

scholarly journals Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications

2018 ◽  
Vol 19 (10) ◽  
pp. 3064 ◽  
Author(s):  
Hirofumi Okubo ◽  
Akifumi Kushiyama ◽  
Yusuke Nakatsu ◽  
Takeshi Yamamotoya ◽  
Yasuka Matsunaga ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Treatment Strategies ◽  
Alcoholic Fatty Liver ◽  
Glucagon Like Peptide 1 ◽  
Global Increase ◽  
Underlying Mechanisms ◽  
Alcoholic Fatty Liver Disease

The rising prevalence of non-alcoholic fatty liver disease (NAFLD) parallels the global increase in the number of people diagnosed with obesity and metabolic syndrome. The gut-liver axis (GLA) plays an important role in the pathogenesis of NAFLD/non-alcoholic steatohepatitis (NASH). In this review, we discuss the clinical significance and underlying mechanisms of action of gut-derived secretory factors in NAFLD/NASH, focusing on recent human studies. Several studies have identified potential causal associations between gut-derived secretory factors and NAFLD/NASH, as well as the underlying mechanisms. The effects of gut-derived hormone-associated drugs, such as glucagon-like peptide-1 analog and recombinant variant of fibroblast growth factor 19, and other new treatment strategies for NAFLD/NASH have also been reported. A growing body of evidence highlights the role of GLA in the pathogenesis of NAFLD/NASH. Larger and longitudinal studies as well as translational research are expected to provide additional insights into the role of gut-derived secretory factors in the pathogenesis of NAFLD/NASH, possibly providing novel markers and therapeutic targets in patients with NAFLD/NASH.

A Systematic Review of the Non-Alcoholic Fatty Liver Disease (NAFLD) Treatment Strategies

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S531-S532
Author(s):  
Muhammad Tahir ◽  
Anthony Martinez ◽  
Naveen Prasad Gopalakrishnan Ravikumar ◽  
Kehua Zhou
Keyword(s):  
Systematic Review ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Treatment Strategies ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Non-alcoholic fatty liver disease and childhood obesity

2020 ◽  
Vol 106 (1) ◽  
pp. 3-8 ◽  
Author(s):  
Meera Shaunak ◽  
Christopher D Byrne ◽  
Nikki Davis ◽  
Paul Afolabi ◽  
Saul N Faust ◽  
...  
Keyword(s):  
Liver Disease ◽  
Childhood Obesity ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Treatment Strategies ◽  
Short Review ◽  
Alcoholic Fatty Liver ◽  
Obesity Epidemic ◽  
Early Disease Detection ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) in children and adolescents has an estimated prevalence of 36.1% in the context of obesity. This figure is anticipated to increase in conjunction with the global obesity epidemic. Worryingly, NAFLD in childhood persisting into adulthood is likely to be harmful, contributing to significant hepatic and extrahepatic morbidities. Early disease detection is required, although the optimum timing, frequency and mode of screening remains undetermined. While the efficacy of several medications, antioxidants, fatty acid supplements and probiotics has been investigated in children, healthy eating and physical activity remain the only prevention and treatment strategies for paediatric NAFLD. This short review discusses the epidemiology, diagnosis, pathogenesis and management of NAFLD in childhood obesity.

Sign in / Sign up

Export Citation Format

Share Document